Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

San Francisco, California


Purpose:

Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD). Aricept has been shown to improve the memory and thinking abilities, activities of daily living and global function in patients. The purpose of the study is to further investigate the effectiveness and safety of donepezil in patients with severe Alzheimer's disease. Donepezil is thought to work in the brain by increasing the levels of an important brain chemical called acetylcholine. This chemical helps a person's memory to work better.


Criteria:

Inclusion Criteria: - Clinically diagnosed Alzheimer's Disease with MMSE score 1~12 - Have not been treated by any medication for Alzheimer's Disease in past 3 months - Live in community or Assisted Living Facility - Healthy or with chronic diseases that are medically controlled or stabilized - Able to swallow tablets Exclusion Criteria: - Any primary neurological or psychiatric diagnosis (including depressive disorder) other than Alzheimer's Disease - Dementia caused by organic diseases other than Alzheimer's Disease


NCT ID:

NCT00096473


Primary Contact:

Study Director
Sharon Richardson, Ph.D.
Eisai Inc.


Backup Contact:

N/A


Location Contact:

San Francisco, California
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.